These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 33805481)

  • 1. Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma.
    Radocha J; van de Donk NWCJ; Weisel K
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
    Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
    Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belantamab mafodotin for the treatment of multiple myeloma.
    Wang B; Wu C; Zhong Q; Ling L; Wu Z; Yu B; Gao X; Zeng H; Yang DH
    Drugs Today (Barc); 2021 Nov; 57(11):653-663. PubMed ID: 34821879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
    Ray U; Orlowski RZ
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal Antibodies in the Treatment of Multiple Myeloma.
    van de Donk NWCJ; Zweegman S
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):337-360. PubMed ID: 38151402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
    Offidani M; Corvatta L; Morè S; Olivieri A
    Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Based Treatment Approaches in Multiple Myeloma.
    Hosoya H; Sidana S
    Curr Hematol Malig Rep; 2021 Apr; 16(2):183-191. PubMed ID: 33730360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.
    De Luca F; Allegra A; Di Chio C; Previti S; Zappalà M; Ettari R
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma.
    Ketchum EB; Clarke A; Clemmons AB
    J Adv Pract Oncol; 2022 Jan; 13(1):77-85. PubMed ID: 35173991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current antibody-based therapies for the treatment of multiple myeloma.
    Varga C; Waldschmidt JM; Gandolfi S; Richardson PG
    Clin Adv Hematol Oncol; 2020 Nov; 18(11):736-748. PubMed ID: 33406065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
    Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses.
    Musto P; La Rocca F
    Expert Rev Hematol; 2020 Apr; 13(4):331-349. PubMed ID: 32153224
    [No Abstract]   [Full Text] [Related]  

  • 13. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.
    Lassiter G; Bergeron C; Guedry R; Cucarola J; Kaye AM; Cornett EM; Kaye AD; Varrassi G; Viswanath O; Urits I
    Curr Oncol; 2021 Jan; 28(1):640-660. PubMed ID: 33494319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.
    Sheikh S; Lebel E; Trudel S
    Future Oncol; 2020 Dec; 16(34):2783-2798. PubMed ID: 32875817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab.
    Shen F; Shen W
    Technol Cancer Res Treat; 2022; 21():15330338221106563. PubMed ID: 35903924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma.
    Shah B; Gray J; Abraham I; Chang M
    J Oncol Pharm Pract; 2023 Jan; 29(1):170-182. PubMed ID: 35726199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
    Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
    Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment.
    Morè S; Petrucci MT; Corvatta L; Fazio F; Offidani M; Olivieri A
    Pharmaceuticals (Basel); 2020 Nov; 13(12):. PubMed ID: 33260960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies as an addition to current myeloma therapy strategies.
    Jullien M; Touzeau C; Moreau P
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.